Rani: 'Program Prioritization'

  Cash runway extended into 2025 -

- Cash runway expected to extend beyond topline results from Phase 2 trial for RT-102, topline results from Phase 1 trial for RT-111, and development of RaniPill® HC to be Phase 1 ready -

- Expansion of manufacturing footprint is expected to enable increased scale and support capacity for potential partner programs -

- RT-101 program discontinued; RT-105 and RT-110 programs paused -

- The company will reduce its workforce by approximately 25% -

https://www.globenewswire.com/news-release/2023/11/01/2771720/0/en/Rani-Therapeutics-Announces-Strategic-Program-Prioritization-Expansion-of-Manufacturing-and-Plans-to-Streamline-Business-Operations-to-Support-Near-Term-Value-Drivers-and-Long-Term.html